BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [1] The acute treatment of episodic and chronic migraine in the United States
    Boruchow, Scott
    Lipton, Richard
    Bigal, Marcelo
    NEUROLOGY, 2008, 70 (11) : A152 - A152
  • [2] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Simone Quintana
    Marco Russo
    Gian Camillo Manzoni
    Paola Torelli
    Neurological Sciences, 2022, 43 : 5757 - 5758
  • [3] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Quintana, Simone
    Russo, Marco
    Manzoni, Gian Camillo
    Torelli, Paola
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5757 - 5758
  • [4] Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
    Ruff, Dustin D.
    Ford, Janet H.
    Tockhorn-Heidenreich, Antje
    Sexson, Matthew
    Govindan, Sriram
    Pearlman, Eric M.
    Wang, Shuu-Jiun
    Khan, Arif
    Aurora, Sheena K.
    CEPHALALGIA, 2019, 39 (08) : 931 - 944
  • [5] Effectiveness of Erenumab-aooe, Fremanezumab-vfrm and Galcanezumab-gnlm in Migraine Patients at Tertiary Headache Clinic with Emphasis on High-Frequency Migraine Patients
    McCurry, Roxanne
    Krashin, Daniel
    Schorn, Melissa
    Chan-Goh, Sau Mui
    Budica, Marcel
    Murinova, Natalia
    NEUROLOGY, 2020, 94 (15)
  • [6] Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
    di Cola, Francesca Schiano
    Bolchini, Marco
    Caratozzolo, Salvatore
    Ceccardi, Giulia
    Cortinovis, Matteo
    Liberini, Paolo
    Rao, Renata
    Padovani, Alessandro
    NEUROLOGY INTERNATIONAL, 2023, 15 (01): : 273 - 284
  • [7] Fremanezumab as a preventive treatment for episodic and chronic migraine
    Bigal, Marcelo E.
    Walter, Sarah
    Rapoport, Alan M.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 719 - 728
  • [8] Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States
    Milev, S.
    Pohl, G. M.
    Sun, A.
    Mason, O.
    Njuguna, N.
    Loo, L.
    HEADACHE, 2020, 60 : 64 - 64
  • [9] Budget impact of lasmiditan for the acute treatment of migraine in the United States
    Milev, Sandra
    Pohl, Gerhardt
    Sun, Ariel
    Mason, Oksana
    Njuguna, Nancy
    Loo, Li Shen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12) : 1714 - 1723
  • [10] HEALTHCARE UTILIZATION AND COSTS AMONG PATIENTS WITH EPISODIC MIGRAINE INITIATING GALCANEZUMAB VERSUS RIMEGEPANT FOR MIGRAINE PREVENTION IN THE UNITED STATES
    Kim, G.
    Hoyt, M.
    Durica, J.
    Zakharyan, A.
    Wallem, A.
    Viktrup, L.
    VALUE IN HEALTH, 2024, 27 (06) : S391 - S391
12345